2,2-dimethylbutyric acid oral pharmaceutical compositions
The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.
1. An oral pharmaceutical composition comprising a pharmaceutically effective amount of 2,2-dimethylbutyric acid, or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable carrier;
wherein the pharmaceutical composition is for oral administration; and
wherein the 2,2-dimethylbutyric acid has an in vivo half-life of greater than about 15 minutes.
2. The oral pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises a pharmaceutically effective amount of the sodium salt of 2,2-dimethylbutyric acid.
3. The oral pharmaceutical composition of claim 1 , wherein the oral pharmaceutical composition is in the form of a liquid, pill, capsule or tablet.
4. The oral pharmaceutical composition of claim 3 , wherein the oral pharmaceutical composition is in the form of a capsule.
5. The oral pharmaceutical composition of claim 3 , wherein the oral pharmaceutical composition is in the form of a tablet.